CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...
Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE...
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...
CAMBRIDGE, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...
CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,...
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END
MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased...
A patient’s death shook Intellia Therapeutics and sank its stock. Should investors buy the dip or steer clear?
Intellia’s shares plunged 23% after its Q3 results showed a pipeline setback. Nonetheless, Cathie Wood’s stake in the company is expanding.
One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures...